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1. Introduction
Prostate cancer (PCa) is a long latency type of tumour that usually develops in men older
than 50 years of age. Prostate epithelial neoplasia (PIN), the initial malignant lesion, pro‐
gresses to invasive carcinoma over the course of years. Because of the particular features of
prostate carcinogenesis, this type of tumour may represent a paradigm for cancer preven‐
tion. The lack of a comprehensive aetiology for prostate cancer and the need for an effective
and inexpensive biological treatment modality, devoid of side effects, has resulted in a mul‐
titude of therapeutic trials. Present evidence suggests that chemo preventive agents may be
used in cancer treatment (Tallberg et al. 2008; Crohns et al. 2009). Because they are consid‐
ered pharmacologically safe and derived from natural sources, most chemo preventive
agents can be used in combination with chemotherapeutic agents to enhance the effect at
lower doses and thus minimize chemotherapy-induced toxicity. There are various therapies
that can successfully reduce the size of tumours, however, often patients suffer a relapse and
the tumour re-grows. Some researchers believe that this happens because the therapies fail
to eradicate a small proportion of cells that drive tumour growth known as cancer stem
cells. They believe that these are the cells that should be targeted to eliminate the tumour
forever.
Today, cancer is considered to be a complex multistep disorder, the result of a combination
of factors including exposure to radiation and/or carcinogens (damage to DNA), infection,
genetics, aging, immune function disorders, and lifestyle factors such as smoking (Nelson et
al. 2003; Mahan et al. 2004). Several clinical trials have evaluated the effect of dietary nu‐
trients on prostate tumour development. These dietary agents may help to suppress the
transformative, hyper proliferative and inflammatory processes that initiate carcinogenesis.
The curative effect does not seem to involve apoptosis (Tallberg and Atroshi, 2011).
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Most human diseases are due to chronic inflammation resulting in loss of  function of a
joint,  a  blood  vessel  or  an  entire  organ.  In  some  organs,  such  as  the  heart  and  brain,
acute inflammation can be fatal. Oxidative stress is a major by-product of cellular metab‐
olism  and  its  regulation  is  critical  for  preventing  disease  and  aging.  Levels  of  reactive
oxygen species  (ROS)  are  generally  higher  in  proliferating  tumour  cells  than in  normal
cells,  and this may explain why ROS is a key component in the efficacy of chemothera‐
peutic drugs (Crohns et al. 2009).
This review focuses on the mechanisms of free radical formation and ROS signalling in pros‐
tate cancer on the basis of current literature. We also highlight the mechanisms by which in‐
flammatory processes contribute to prostatic carcinogenesis and how antioxidants react to
neutralize free radicals.
2. Prostate cancer as an age-related disease
Prostate cancer is the common among men in the developed world. The risk increases after
the age of 50 (Sakr et al., 1994; Abate-Shen and Shen, 2000; Schaeffer, 2003; Yancik 2005). Ag‐
gressive treatment for older men is not advisable because of an increased risk of short-term
and long-term treatment-related adverse effects (Lu-Yao et al. 1999). The development of
cancer lesions can be in two different regions of the prostate gland, in the peripheral zone,
which is most common, and the remaining lesions are found in the transition zone located in
the periurethral region (McNeal, 1988). Prostatic cancer multifocality makes accurate clinical
staging difficult, and repeated revisions have been undertaken in an effort to optimize prog‐
nostic accuracy (McNeal, 1988; Andreoiu and Cheng, 2010).
Normal aging is  associated with changes in body composition. While treatments for the
disease continue to improve with each passing decade, the disease itself  has likely been
around since ancient times. Recently it was documented that a mummy - thought to be a
man in  his  50s  -  had  numerous  sclerotic  spots  throughout  the  bones  of  his  pelvis  and
lower spine that were most consistent in appearance with metastases from prostate can‐
cer (Prates et al., 2011).
3. Risk factors for prostate cancer
The  etiological  factors  associated  with  prostate  cancer  are  poorly  studied  compared  to
other common cancers. It is suggested that diet (Fair et.  1997; Schulman et al.  2001) and
environmental  differences  (Muir  et  al.  1991)  play  important  roles  (Shimizu  et  al.,  1991;
Minami et  al.,  1993).  For example,  it  is  not  known whether decreasing fat  or  increasing
fruits  and  vegetables  in  the  diet  helps  to  decrease  the  risk  of  prostate  cancer  or  death
from prostate  cancer.  High intake  of  fat,  especially  total  fat  and saturated fat,  is  a  risk
factor for prostate cancer (Andersson et al. 1996; Kolonel, 2001). This has been explained
by  the  evidence  indicating  that  fat  may  be  mediated  through  endogenous  hormones
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(Bosland,  2000).  Phytoestrogen  metabolites  have  been  studied,  and  dietary  habits  are
probably an important factor contributing to the geographic variations observed in some
Asian men compared to European men, which may explain the low incidence of prostate
cancer in Asia (Adlercreutz et al., 1993).
4. Mechanism of prostate cancer cell
Living cells have three main systems for protection and repair under oxidative stress: (1) di‐
rect antioxidant enzymes (Superoxide dismutase (SOD), catalase, peroxidises), (2) proteases
and phospholipases activated by oxidative modification of membranes, (3) lipid and water
soluble antioxidants (Sies, 1997; Finkel and Holbrook, 2000). Normalization of malignant
gene transcription in an organ requires dietary correction of the etiologic long-standing met‐
abolic deficiency involving six or more inter-linked natural factors aided by hormonal equi‐
librium, enhanced by specific autologous immunotherapy. In bio-immunotherapy this
therapeutic bio-modulation is aims to simulate specific leukaemia, adenocarcinoma or sarco‐
ma regulatory codes, leading to cancer cure by forcing tumour cells back into healthy gene
transcription, without apoptosis. According to Lukacs et al. (2010), prostate cancer can be in‐
itiated by so many different mutations, and if a key regulator of self-renewal can be found,
then partially one may control the growth of the cancer, no matter what the mutation is.
Their approach, which aims to attack the process that allows the cancer cells to grow indefi‐
nitely, may provide an alternative way of treating cancer by targeting the core mechanism of
cancer cell self-renewal and proliferation (Lukacs et al.2010).
Cells are often exposed to a high load of oxidants and free radicals. Oxidative stress can
occur  as  a  result  of  increased  metabolic  rate,  increased  oxygen  tension,  compromise  of
normal cellular antioxidants and many others endogenous and exogenous factors (Figure
1). Cell motility is a complex biological process, involved in development, inflammation,
homeostasis,  and  pathological  processes  such  as  the  invasion  and  metastatic  spread  of
cancer  (Collins  et  al.  2006).  Cancer  metabolism is  a  factor  that  might  be  exploited  as  a
potential  therapeutic  target  for  drug  discovery  also  on  how  a  cancer  cell  differs  in  its
metabolism to that of a rapidly proliferating normal cell (Vander Heiden et al. 2009). By
small  interfering RNA–based functional screening of over 200 metabolic enzymes,  trans‐
porters,  and regulators to identify those selectively required for prostate cancer cell  sur‐
vival.  Ros  and  co-workers  showed  that  treatment  with  a  chemical  antioxidant  rescued
the viability of PFKFB4 (one of the genes identified) -deficient prostate cancer cells,  fur‐
ther suggesting that PFKFB4 mediates ROS detoxification in cancer cells.  Together, these
findings reveal  that  prostate  cancer  cells  are  exquisitely sensitive to  metabolic  perturba‐
tions  that  affect  the  balance  between  glucose  and  the  pentose  phosphate  pathway  and
implicate PFKFB4 as a potential therapeutic target (Ros et al 2012).
Under normal conditions, the antioxidant defence systems are probably capable of main‐
taining a low steady-state level of damage and thus protecting the cells (Zhou et al.2003).
Among the risk factors for the development of prostate cancer are ageing and lifestyle. Un‐
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der situations of oxidative stress and with increasing age the organism may not be able to
maintain homeostasis with deleterious and potentially unfortunate consequences.
Figure 1. The prostanoid system may belong to the adaptive mechanisms by which the cell reacts to its environment.
The reaction may be triggered by chemical, mechanical and other stimuli. Prostacyclin (PGI2) and PGE2 stimulate AT‐
Pases and the formation of intracellular cyclic AMP, which usually stabilize the cell membrane. TXA2 among others
may activate calcium-related processes which may lead to smooth muscle contraction, platelet aggregation and secre‐
tory events. PGE2 has the capacity for both excitatory and inhibitory activities and it is often released in stressful situa‐
tions. (Parantainen et al.1988)
5. Inflammation and prostate cancer
Inflammation involves the induction of complex, coordinated chemical signals and associat‐
ed physiological processes following injury that promote “healing” of damaged tissues
(Balkwill and Mantovani, 2001; Rakoff-Nahoum, 2006; Mantovani et al, 2008). Early respons‐
es include increases in vascular permeability and activation, together with the directed mi‐
gration of leukocytes (neutrophils, monocytes and eosinophils) towards the site of injury,
where the ground-work is being laid for the formation of a new extracellular matrix. The di‐
rectional migration is mediated by secreted chemokines that form a concentration gradient
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towards the site of inflammation (Koopmann and Krangel, 1997). The extracellular matrix
provides the structure upon which cells (fibroblasts and endothelial cells) can migrate and
proliferate, regenerating new tissue and a vascular network. In later stage of the inflamma‐
tory response, the macrophages are the dominant cell type, orchestrating and directing the
healing process. Normally, inflammation is a self-limiting process due to the production of
anti-inflammatory cytokines, which buffer the effect of pro-inflammatory cytokines. The cy‐
tokine/chemokine pattern persisting at the inflammatory site is important in the develop‐
ment of chronic disease. Deregulation of any of the cooperating factors can lead to
prolonged inflammation with chronic exposure to cytotoxic mediators (Coussens and Werb,
2002). Chronic inflammation can be caused by a variety of factors, including bacterial, viral,
and parasitic infections, chemical irritants, and non-digestible particles, but often the under‐
lying cause is unknown. The longer the inflammation persists, the higher the risk of associ‐
ated carcinogenesis (Shacter et al., 2002, Coussens and Werb, 2002).
At the site of inflammation, caused by either wounding or infection, phagocytic cells (e.g.
neutrophils and macrophages) generate reactive oxygen and nitrogen substances (Atroshi et
al. 1988; Gallin, 1992), but these cells also synthesize and secrete large quantities of growth
factors and a number of potent angiogenic factors, cytokines, and proteases, all of which are
important mediators in the tissue regeneration, but can also potentiate neoplastic tumori‐
genesis. Prostaglandins, cytokines, nuclear factor NFkB, chemokines and angiogenic factors
are the main molecular players that link inflammation to genetic alterations. However, free
radical species derived from oxygen (ROI) and nitrogen (RNI) are the main chemical effec‐
tors (Jackson et al. 1997; Baron and, Sandler, 2000; Federico et al. 2007). Various carcinomas
(including cancers of the liver, bladder, colon, stomach, and oesophagus) have been shown
to arise from areas of infection and inflammation (Federico et al. 2007). Over 15% of all ma‐
lignancies worldwide are attributable to infectious agents, and inflammation is a major com‐
ponent of these chronic infections (Kuper et al., 2000; Ibrahim and Makkiya, 2011). Colon
cancers arising in individuals with inflammatory bowel disease (e.g. chronic ulcerative coli‐
tis or Crohn’s disease) and stomach cancers caused by chronic Helicobacter pylori infection
are among the most intensively studied and well established types of cancer associated with
inflammation of different origins (Coussens and Werb, 2002).
6. The role of inflammation in the pathogenesis of prostate
Although it has been established that chronic inflammation plays a causative role in the de‐
velopment of many human cancers, the contribution of inflammatory processes to the devel‐
opment of prostate cancer has not been extensively studied. Bioactive food components are
increasingly being evaluated as potential prostate chemopreventive agents (Barqawi et al.
2004; Chong and Rashid, 2005; Sonn, et al. 2005; Hsu et al 2010; Schellhammer, 2012). One
such agent is resveratrol, a phytochemical which has been considered as a chemopreventive
for human prostate cancer (Ratan et al. 2002; Stewart et al. 2003 ).
The contribution of inflammatory intermediates such as eicosanoids in cancer initiation and
progression is another area of interest. These intermediates might form the link between in‐
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flammation and cancer. Interest in the relationship between chronic prostatic inflammation
and prostate cancer is increasing. Proliferative inflammatory atrophy, or proliferative in‐
flammatory atrophy (PIA), consists of lesions in the prostate characterized by atrophy of the
epithelium and by an increased proliferative index (De Marzo et al. 1999). These lesions are
common in older men and have been hypothesized to be a precursor of prostate cancer (Nel‐
son et al. 2004; De Marzo et al. 2007). More knowledge about the risk factors could lead to
better preventive measures together with better treatments.
Evidence suggests that inflammation is vital for the aetiology of prostate cancer and the
pathogenesis of PCa reflects both hereditary and environmental components. These evi‐
dence stems from epidemiological, histopathological and molecular pathological studies
(Ames et al., 1995; De Marzo et al. 1999; Coussens and Werb, 2002). More general evidence
of a relationship between inflammation and prostate cancer has been provided by reports
indicating that daily use of non-steroidal anti-inflammatory drugs (NSAIDs) may be associ‐
ated with a reduce incidence of prostate cancer (Gupta et al. 2000). The exact mechanism
whereby inflammation might act in tumour development and progression remains to be
elucidated, but is likely to be complex.
Some studies have suggested that prostatitis, inflammation of the prostate gland that in‐
cludes acute or chronic bacterial infection, may be linked to an increased risk of prostate
cancer (Dennis et a. 2002; Roberts et al. 2004). This link was explained that chronic inflam‐
mation within the prostate due to the exposure of microbial agents stimulates the produc‐
tion of ROS and inflammatory cytokines leading to carcinogenesis (Coussens and Werb,
2002; De Marzo et al. 2007).
Chronic inflammation has been associated with the development of malignancy in several
other organs such as the oesophagus, stomach, colon, liver and urinary bladder. Inflamma‐
tion is thought to incite carcinogenesis by causing cell and genome damage, promoting cel‐
lular turnover, and creating a tissue microenvironment that can enhance cell replication,
angiogenesis and tissue repair. Epidemiological data have correlated prostatitis and sexually
transmitted diseases with an increased risk of prostate cancer and intake of anti-inflammato‐
ry drugs and antioxidants with a decreased risk. Evidence from genetic and molecular stud‐
ies also supports the hypothesis that prostate inflammation and/or infection may be a cause
of prostate cancer. In 1999 De Marzo et al proposed that proliferative inflammatory atrophy
(PIA) is a precursor to PIN and cancer. Further research will provide opportunities for the
discovery and development of strategies for treatment and prevention of prostate cancer
(Sugar, 2006).
Accumulating epidemiologic and molecular evidence suggests that inflammation is an im‐
portant component in the aetiology of prostate cancer. Supporting this hypothesis, popula‐
tion studies have found an increased risk of prostate cancer in men with a prior history of
certain sexually transmitted infections or prostatitis. More general evidence of a relationship
between inflammation and prostate cancer has been provided by reports indicating that dai‐
ly use of non steroidal anti-inflammatory drugs (NSAIDs) may be associated with a lower
incidence of prostate cancer. The exact mechanism whereby inflammation might act in tu‐
mour development and progression remains to be elucidated, but is likely to be complex.
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Cancer lesions can develop in two different regions of the prostate gland, most commonly
(in ~80% of cases) in the periphery zone, while most of the remaining lesions are found in
the transition zone, which is located in the periurethral region (McNeal, 1968, 1988).
7. Possible interaction between prostaglandins and glutathione
metabolism in prostate cancer
Prostaglandins (PGs) constitute a whole family of peroxidized lipids formed in most cells.
Almost any kind of stimuli be it mechanical, chemical, physiological or traumatic, may ini‐
tiate the formation of different kinds of PGs (Atroshi et al. 1986). Thus the particular impor‐
tance of the local PG-impact is usually very difficult to evaluate. Some PGS, like PGEs and
PGI2 (prostacyclin), are potent triggers of inflammatory symptoms. The main roles for PGEs
and PGI2 in inflammation may in fact be in the generation of hyperalgesia, sensitization of
the tissue to the irritant and pain producing activity of the amine and peptide type of media‐
tors of inflammation (Ferreira and Nakamura, 1979; Ferreira 2002). On the other hand, these
PGs have a marked tissue protective function, e.g. in preventing vasoconstriction and plate‐
let aggregation. Other prostanoids (PG-like substances), like PGD2, PGF2α and thromboxane
A2 (TXA2), are mostly vasoconstrictors. Their formation may be associated with allergic and
other reactions of hypersensitivity, and TXA2 is a very potent aggregator of platelets.
Prostaglandins play a role in the regulation of several important physiological and patho‐
logical processes, and evidence (Marnett, 1992; Thun et al., 1991; Taketo, 1998; Samuelsson
et al., 2007) suggests that they could be involved in tumour progression. Studies have dem‐
onstrated that PGE2 and its EP receptors are implicated in promoting carcinogenesis in dif‐
ferent types of cancer (Wang and Klein, 2007). Arachidonic acid (AA) is the precursor for
prostaglandin E2 (PGE2) synthesis and increases growth of prostate cancer cells (Van et al.,
1998). However, the real sources of PGs are not well known and are a matter of speculation.
For example we do not know for sure if the PGs originate in the blood, inflamed tissue, etc.
There are several possibilities:
1. Bacterial toxins might contribute to the PG-release (figure 2). This was clearly demon‐
strated by Giri and coworkers (1984), and similar mechanisms might operate in the
spontaneous disease as well (Liu et al. 2011; Sanz-Motilva et al. 2012).
2. The production of PGs is greatly increased by polymorphonuclear leukocytes. Neutro‐
phil invasion is a typical feature in inflammation (Atroshi et al. 1988).
3. Changes in tissue protein and electrolyte contents are factors that have marked effects
on PG-production (atroshi et al. 1988). Albumin is a typical factor increasing the forma‐
tion of PGs, particularly that of PGF2α.
4. Inflammatory mediators are factors that might contribute to the formation of PGs. (e.g.
monoamines and peptide hormones).
Prostate Cancer, Inflammation and Antioxidants
http://dx.doi.org/10.5772/53296
407
Figure 2. Possible interaction between erythrocyte and inflamed tissue during infection/inflammation. Oxygen free
radicals produced by hypoxia, bacterial toxins and phagocytosis increase lipid peroxidation and peroxidative stress in
the erythrocyte. Pyogenic bacteria as well as white cells may stimulate the synthesis of mucoproteins. The pus formed
has antioxidant activity and the formation of oxygen free radicals is needed. GSH and other antioxidant enzymes rep‐
resent the intracellular charged compounds, potential sources of reducing equivalents. The intracellular enzymes
(GSH, GSHPX etc.) may greatly affected by oxygen free radicals and lipid peroxidation associated e.g. in infection, hy‐
poxia and cancer. Destruction of erythrocytes is one possible source of GSH and other antioxidant enzymes which are
elevated in the inflamed tissue. (Atroshi et al.1986)
8. Possible importance of leukotrienes
Leukotrienes (LTs) are biologically active fatty acids derived from the oxidative metabolism
of arachidonic acid through the 5-lipoxygenase pathway (Matsuyama et al. 2010; Haegg‐
ström and Funk, 2011). Leukotrienes and other lipoxygenase products are synthesized from
the same precursor fatty acids as PGs, and substantial changes in PG/LT balance are possible
during inflammation and infection (Figure 3). LTs are highly vasoactive, and together with
PGs they may contribute to the local haemodynamic changes in the inflamed tissue. More‐
over, some LTs are very active leukotactic agents, and LTB4 in particular could contribute to
the massive invasion of neutrophils in the inflammatory area. PGE2 and LTB4 are involved
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in inflammation and carcinogenesis in several tissues. PGE2 and inflammation may be asso‐
ciated to stromal benign prostatic hyperplasia whereas LTB4 may play a role in prostate car‐
cinogenesis; cancerous samples had higher LTB4 levels than pericancerous samples, but
there was no difference in PGE2 levels (Larré et al. 2008).
Figure 3. Enzymes with peroxidase activity are needed to reduce the endoperoxide PGG2 to PGH2 (1), and specific
isomerases resembling GSH-S-transferase (2) reduce PGH2 further to PGs and prostacyclin (3). GSH and GSH-enzymes
are involved in the formation of leukotrienes as well. One molecule of GSH (4) is attached to LTA 4 to form LTC4, the
first of the cysteinyl leukotrienes (C, D, E). The peroxidative capacity of erythrocytes may participate in the conversion
of LTA 4 to LTB4. Peroxidases are also needed to reduce other lipid hydroperoxides to corresponding alcohols (6) to
prevent the enzyme destruction caused by oxygen free radicals (7). The activity of LTB4 may be mediated by PGs (5).
(Atroshi et al. 1986)
Lipoxygenase-like activities are seen in the phagocytosis and bacterial killing. Lipid peroxi‐
dation as such is a source of oxygen free radicals. On the other hand, the radicals are among
the most potent triggerers of lipid peroxidation. Some free radicals, particularly the hydrox‐
yl radical (•OH) are very toxic to the tissues. During reduction of the 15-hydroperoxide, to
the corresponding alcohol •OH is formed and the enzyme systems that form PGI2 may be
injured. Leukotriene B4 (LTB4) has been implicated in prostate and colon carcinogenesis. The
anticancer effect of celecoxib is COX-2-independent in HT-29 and PC-3 cells and in HT-29
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cells primarily via down-regulating LTB4 production (Gao et al., 2010). Matsuyama and co-
workers (2010) have demonstrated that CysLT1R expressed in urological cancer may play a
crucial role in carcinogenesis and may therefore be a novel target in the treatment of urolog‐
ical cancer. An increasing body of evidence supports an acute role for 5-LO products al‐
ready during the earliest stages of pancreatic, prostate, and colorectal carcinogenesis
(Steinhilber et al., 2010).
9. The role of GSH-enzymes in the metabolism of arachidonic acid
The tissue content of GSH is normally very high, in some tissues the level is up to the 5 mM.
The functions of GSH are often tissue protective, and there are numerous enzymes in which
GSH plays a central role as a cofactor.
Typical GSH-enzymes include GSH-peroxidase (GSH-Px), located in the circulation almost
exclusively in the red cells, various GSH-transferases that have peroxidise-like activity and
bind chemicals and γ-glutamyl transferase which reflects the function of the liver and is in‐
volved in the transport of amino acids across the cell membrane. GSH is also consumed by
some cytochromes, most notably cytochrome P-450.
Several steps in the metabolism of arachidonic acid may be normally regulated by GSH-en‐
zymes (Rouzer et al. 1982). It was an early observation that GSH may function as a chemical
cofactor or coenzyme in the formation of some PGs, particularly PGEs (Mimata et al. 1988).
Specific, atypical GSH-S-transferases are needed in the isomeration of PG-endoperoxides
(the intermediary step) to PGEs and PGDs (Hubatsch et al. 2002). Ghosh (2004) demonstrat‐
ed that selenium significantly reduced the incidence of clinical prostate cancer. A high in‐
take of dietary fat containing arachidonic acid or its precursor fatty acids should be
administered when selenium is used for the management of prostate cancer, as it has been
suggested that a combination of selenium and 5-lipoxygenase inhibitors may be an effective
regimen for prostate cancer control (Ghosh and Myers, 1998; Ghosh, 2004). A low prostatic
arachidonic acid level was found in patients undergoing prostate surgery for either benign
or malignant disease. Showed a low prostatic arachidonic acid level, which was explained as
a result of the increased use of arachidonic acid for the production of prostaglandins and/or
leukotrienes (Faas et al. 2003; Tilg and Moschen, 2006; Calder 2012 ).
There is little data available on these parameters in the prostate. Richie et al (2012), working
with age related changes in selenium and glutathione levels in different lobes of the rat
prostate found an increased level of oxidative stress together with decreases in selenium and
the major cellular antioxidant glutathione (GSH). They compared the levels of selenium,
GSH and protein-bound GSH (GSSP) in blood and prostate tissues in rats. Their findings of
age-related changes in GSSP and selenium in the DL prostate are consistent with the sensi‐
tivity of this lobe to carcinogenesis and, thus, may be playing a mechanistic role (Richie et al.
2012). Selenium is an integral part of GSH peroxidase, the enzyme that mediates antioxi‐
dants by glutathione (Parantainen et al. 1988). Studying the metabolic profiles of human
prostate cancer tissues it was shown a significant decrease in reduced glutathione (GSH)
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during cancer progression from low- to high-grade Gleason scores (Sreekumar et al. 2009;
Pavlou and Diamandis, 2009). Some studies found a lower Se concentration in the whole
blood and plasma in benign prostatic hyperplasia (BPH) patients compared to healthy con‐
trols was observed by Eichholzer et al. (2012); also they found a lower activity of erythrocyte
GPx. A significant inverse association between serum Se concentrations and the risk of BPH
was shown (Eichholzer et al. 2012).
The formation of PGs is a very specific form of lipid peroxidation, and in these processes
GSH-Px may have a central regulatory role. Some pGs inhibit the formation of lipid perox‐
ides, while a certain level of peroxides is needed to maintain normal PG-production (Hemler
and Land, 1980; Sugino et al. 2001). Such a “peroxide tone” is a crucial factor in the regula‐
tion of the metabolism of arachidonic acid in toto. Peroxidases may have a key role in elimi‐
nating the oxygen free radical during the conversion of endoperoxides to corresponding
alcohols. The hydroxyl radical formed from 15-HPETE may thus be trapped (Chance et al.
1979; Flohé and Ursini, 2008).
Considering the circulatory peroxides, the functioning of the erythrocyte GSH-Px may have
a crucial role. During infection and inflammation there may be a marked reduction in the
erythrocyte count. Such anaemia may be due to haemolytic processes in which lipid peroxi‐
dation and the formation of free radicals may be the key event.
In the formation of leukotrienes, the GSH-enzymes γ-GT and GSH-S-transferases have a key
role. The whole group of cysteinyl leukotrienes are formed by adding GSH to LTA4, which
gives rise to LTC4 and, when the GSH is split, to LTD4, LTE4 and LTF4. In the formation of
the other type, LTB4, GSH does not have a direct role (Morris et al.1981). However, LTA4 is
reduced to LTB4 on contact with erythrocytes, which points to a certain importance of the
peroxidise-like mechanisms, possibly GSH-Px, so abundant in the red cell. Leukotriene B4
(LTB4) is a potent lipid mediator of inflammation, implicated in numerous diseases includ‐
ing prostate cancer. An LTB4 tissue level was shown to play a role in in benign and cancer‐
ous prostates. Cancerous from patients’ sample had higher LTB4 than pericancerous samples
(Larre et al. 2008).
10. Diet, inflammation and prostate cancer
The causes of cancer have been largely attributed to genetic and environmental factors, includ‐
ing lifestyle, and are generally thought of as either avoidable or unavoidable. Dietary habits
have been considered for years in epidemiological and case controlled studies to have an im‐
pact on cancer development and prevention. However, this association between diet and can‐
cer has never been as clear as the correlation between smoking and cancer. Differences in diet
and lifestyle may account for the variability of prostate cancer rates in different countries (Man‐
olio et al. 2009). Good nutrition may reduce the incidence of prostate cancer and help reduce
the risk of prostate cancer progression (Miller et al 2012). Several studies suggest a relationship
between diet and prostate cancer risk; however, nutritional studies are difficult to perform be‐
cause of the inherent heterogeneity of any study population (Klein et al.2006), the variations in
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individual lifestyles, and the quantitative and qualitative complexity in food and food prod‐
ucts (Giovannucci et al, 1993; Huang, 2006). Therefore, randomized and carefully controlled
studies can address the relation between prostate cancer and nutrition.
The importance of nutrition in disease prevention and treatment has gained much attention
in recent years. Diet may represent a modifiable prostate cancer risk factor, but a vegetable-
based prostate-healthy diet is a major change for most men (Carmody et al. 2008). Other
study suggest that keeping the appropriate body mass and level of cholesterol by proper di‐
et and physical exercises may be the prophylaxis of prostate cancer (Pilch et al 2012). The
cancer preventive activity of vitamin E has been suggested by many epidemiologic studies.
Yang and co-workers suggested that vitamin E, as ingested in the diet or in supplements
that are rich in γ- and δ-tocopherols, is cancer preventive; whereas supplementation with
high doses of α-tocopherol is not (Yang et al 2012). It has been suggested that intake of vege‐
tables and fruit plays a role in protecting against prostate cancer development (Chan and
Giovannucci, 2001; Key et al., 2004). Furthermore, vitamins and trace elements have been
studied for their roles in prostate cancer pathogenesis (Chanand Giovannucci, 2001; Moyad
et al. 2002; Tallberg and Atroshi, 2011).
In order to disentangle the association of diet and prostate carcinogenesis better understand‐
ing of the human genome will further accelerate nutrigenomics applications and the devel‐
opment of nutritional modifications including personalized nutrition for our well-being and
will also present a strong influence on future drug discovery (Lundstrom,2012). However,
antioxidant supplements so far tested seem to offer little improvement over a well-balanced
diet, possibly because of the choice of the substances tested or of an excessive dosage (Fair
and Wynder, 1996; Dolara et al. 2012). Future trials of nutritional medication might help to
disentangle the association of diet and prostate carcinogenesis.
The effect of diet can be direct, via the cumulative effect of exposure to nutrients and carci‐
nogens in foods; in this case, the balance of cancer-promoting and -protective substances
may contribute in defining cancer risk (Antila et al. 1996; Adhami and mukhtar, 2012; Adha‐
mi et al.2012). There are also indirect ways by which diet affects the cancer process. These
include the effects of diet on energy balance and risk of obesity and the hormonal and meta‐
bolic responses related to energy balance.
There is an emerging consensus that situations of acute or chronic imbalance between the
antioxidative capacity of cells and tissues, and the production of pro oxidative species, is as‐
sociated with the development of a number of human diseases. Despite enormous interest in
the area of antioxidants as therapeutic tools, the development of foreign compounds as ther‐
apeutic antioxidants has provided little therapeutic benefit.
1. Many important physiological functions, such as the regulation of cell cycle (mitogene‐
sis and apoptosis), are known to be tightly coupled to the induction of controlled epi‐
sodes of oxidative stress in biological systems. This entails problems in terms of
potential side effects for antioxidant therapy, which have been largely ignored in most
clinical use of antioxidants. This may have serious implications for the choice of antioxi‐
dant principle to be used.
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2. The actual choice of antioxidant therapy is it xenobiotic or endogenous, should be indi‐
cated based on sound molecular knowledge of the involvement of oxidative stress in
the actual pathology.
3. Dietary habits are probably an important factor that contributes to the geographic varia‐
tions in prostate cancer rates. A large number of epidemiological studies have investi‐
gated the association between dietary factors and prostate cancer. Epidemiologic
studies on prostate cancer have extensively investigated dietary risk factors (Kolonel,
2001; Park et al. 2007). Suggesting that diet and environmental differences play impor‐
tant roles in prostate cancer (Shimizu et al., 1991; Minami et al.,1993).
11. Conclusion
Cancer is due to the accumulation of DNA mutations that confer a growth advantage and
invasive properties on clones of cells. A variety of external factors including nutrients in the
environment interacting with genetic susceptibility influence the accumulation of mutations
in cells. Nutrition is important at every stage of carcinogenesis from initiation to promotion
to progression and metastasis. In spite of the fact that prostate cancer is the most common
male cancer in many countries in the developed world, little is known of risk factors and
predisposing conditions.
The number of prostate cancer cases around the world is increasing. Its incidence has been
associated with ageing, environmental factors and changes in lifestyle. Based on some re‐
search in animals and people, certain dietary measures have been suggested to prevent the
progression of prostate cancer. However, there is no solid evidence that a healthy diet can
prevent people from developing prostate cancer. The reasons that patients with prostate
cancer are using the dietary supplements are to enhance their health. Such dietary elements
may also limit drug efficiency.
Oxidative  stress  has  been  suggested  to  play  a  key  role  in  carcinogenesis.  Free  radicals
have been shown to mediate the anti-cancer actions of many chemotherapeutic regimens.
Despite  active investigation,  knowledge is  lacking concerning the local  and systemic ef‐
fects of free radical-generating treatments in cancer. Free radicals are among the environ‐
mental factors that might contribute to cancer process (Atroshi et  al.  2010).  While it  has
not been conclusively determined whether free radicals are a cause or an effect of prostate
cancer,  it  is  clear  that  characteristic  types  of  free  radical  damage  increase  with  cancer.
However,  understanding  the  nature  of  that  particular  tumour  can  help  us  to  optimize
therapy  or  to  design  therapeutic  approaches.  Recently,  Maddams  and  co-workers  have
shown that a large increase in cancer can be expected in the oldest age groups in the com‐
ing decades,  and therefore  there  is  an  increased demand upon the  right  treatment  and
health services (Maddams et al. 2012).
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